Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
PD-L1 negative
i
Other names:
PD-L1, CD274, HPD-L1, PD-L1, B7H1, PDL1, Programmed death ligand 1, B7-H1, B7-H, PDCD1L1, PDCD1LG1, PDCD1 Ligand 1, B7 homolog 1, CD274 Antigen, Programmed cell death 1 ligand 1, CD274 molecule
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
29126
Related biomarkers:
Expression
Mutation
CNA
Others
‹
›
Associations
News
Trials
VERI cancer hierarchy
Reset Filters
PD-L1 negative
Squamous Cell Carcinoma of Head and Neck
PD-L1 negative
Squamous Cell Carcinoma of Head and Neck
methotrexate
Sensitive: A2 - Guideline
methotrexate
Sensitive
:
A2
methotrexate
Sensitive: A2 - Guideline
methotrexate
Sensitive
:
A2
PD-L1 negative
Squamous Cell Carcinoma of Head and Neck
PD-L1 negative
Squamous Cell Carcinoma of Head and Neck
TPeX
Sensitive: A2 - Guideline
TPeX
Sensitive
:
A2
TPeX
Sensitive: A2 - Guideline
TPeX
Sensitive
:
A2
PD-L1 negative
Squamous Cell Carcinoma of Head and Neck
PD-L1 negative
Squamous Cell Carcinoma of Head and Neck
pembrolizumab
Sensitive: A2 - Guideline
pembrolizumab
Sensitive
:
A2
pembrolizumab
Sensitive: A2 - Guideline
pembrolizumab
Sensitive
:
A2
PD-L1 negative
Squamous Cell Carcinoma of Head and Neck
PD-L1 negative
Squamous Cell Carcinoma of Head and Neck
cetuximab
Sensitive: A2 - Guideline
cetuximab
Sensitive
:
A2
cetuximab
Sensitive: A2 - Guideline
cetuximab
Sensitive
:
A2
PD-L1 negative
Squamous Cell Carcinoma of Head and Neck
PD-L1 negative
Squamous Cell Carcinoma of Head and Neck
5-fluorouracil
Sensitive: A2 - Guideline
5-fluorouracil
Sensitive
:
A2
5-fluorouracil
Sensitive: A2 - Guideline
5-fluorouracil
Sensitive
:
A2
PD-L1 negative
Melanoma
PD-L1 negative
Melanoma
pembrolizumab
Sensitive: B - Late Trials
pembrolizumab
Sensitive
:
B
pembrolizumab
Sensitive: B - Late Trials
pembrolizumab
Sensitive
:
B
PD-L1 negative
Non Small Cell Lung Cancer
PD-L1 negative
Non Small Cell Lung Cancer
pembrolizumab
Sensitive: C2 – Inclusion Criteria
pembrolizumab
Sensitive
:
C2
pembrolizumab
Sensitive: C2 – Inclusion Criteria
pembrolizumab
Sensitive
:
C2
PD-L1 negative
Non Small Cell Lung Cancer
PD-L1 negative
Non Small Cell Lung Cancer
nivolumab + ipilimumab
Sensitive: C2 – Inclusion Criteria
nivolumab + ipilimumab
Sensitive
:
C2
nivolumab + ipilimumab
Sensitive: C2 – Inclusion Criteria
nivolumab + ipilimumab
Sensitive
:
C2
PD-L1 negative
Non Small Cell Lung Cancer
PD-L1 negative
Non Small Cell Lung Cancer
avelumab + VX15
Sensitive: C3 – Early Trials
avelumab + VX15
Sensitive
:
C3
avelumab + VX15
Sensitive: C3 – Early Trials
avelumab + VX15
Sensitive
:
C3
PD-L1 negative
Non Small Cell Lung Cancer
PD-L1 negative
Non Small Cell Lung Cancer
nivolumab
Resistant: C3 – Early Trials
nivolumab
Resistant
:
C3
nivolumab
Resistant: C3 – Early Trials
nivolumab
Resistant
:
C3
PD-L1 negative
Urothelial Cancer
PD-L1 negative
Urothelial Cancer
nivolumab + IPI-549
Sensitive: C3 – Early Trials
nivolumab + IPI-549
Sensitive
:
C3
nivolumab + IPI-549
Sensitive: C3 – Early Trials
nivolumab + IPI-549
Sensitive
:
C3
PD-L1 negative
Vulvar Cancer
PD-L1 negative
Vulvar Cancer
pembrolizumab
Sensitive: C3 – Early Trials
pembrolizumab
Sensitive
:
C3
pembrolizumab
Sensitive: C3 – Early Trials
pembrolizumab
Sensitive
:
C3
PD-L1 negative
Melanoma
PD-L1 negative
Melanoma
pembrolizumab + ipilimumab
Sensitive: C3 – Early Trials
pembrolizumab + ipilimumab
Sensitive
:
C3
pembrolizumab + ipilimumab
Sensitive: C3 – Early Trials
pembrolizumab + ipilimumab
Sensitive
:
C3
PD-L1 negative
Cervical Cancer
PD-L1 negative
Cervical Cancer
AGEN2034
Sensitive: C3 – Early Trials
AGEN2034
Sensitive
:
C3
AGEN2034
Sensitive: C3 – Early Trials
AGEN2034
Sensitive
:
C3
PD-L1 negative
Head and Neck Cancer
PD-L1 negative
Head and Neck Cancer
ABBV-181
Sensitive: C3 – Early Trials
ABBV-181
Sensitive
:
C3
ABBV-181
Sensitive: C3 – Early Trials
ABBV-181
Sensitive
:
C3
PD-L1 negative
Non Small Cell Lung Cancer
PD-L1 negative
Non Small Cell Lung Cancer
ABBV-181
Sensitive: C3 – Early Trials
ABBV-181
Sensitive
:
C3
ABBV-181
Sensitive: C3 – Early Trials
ABBV-181
Sensitive
:
C3
PD-L1 negative
Triple Negative Breast Cancer
PD-L1 negative
Triple Negative Breast Cancer
pembrolizumab
Sensitive: C3 – Early Trials
pembrolizumab
Sensitive
:
C3
pembrolizumab
Sensitive: C3 – Early Trials
pembrolizumab
Sensitive
:
C3
PD-L1 negative
Cervical Cancer
PD-L1 negative
Cervical Cancer
pembrolizumab + tirvalimogene teraplasmid
Sensitive: C3 – Early Trials
pembrolizumab + tirvalimogene teraplasmid
Sensitive
:
C3
pembrolizumab + tirvalimogene teraplasmid
Sensitive: C3 – Early Trials
pembrolizumab + tirvalimogene teraplasmid
Sensitive
:
C3
PD-L1 negative
Melanoma
PD-L1 negative
Melanoma
nivolumab + IO102-IO103
Sensitive: C3 – Early Trials
nivolumab + IO102-IO103
Sensitive
:
C3
nivolumab + IO102-IO103
Sensitive: C3 – Early Trials
nivolumab + IO102-IO103
Sensitive
:
C3
PD-L1 negative
Lung Non-Squamous Non-Small Cell Cancer
PD-L1 negative
Lung Non-Squamous Non-Small Cell Cancer
bevacizumab
Sensitive: C3 – Early Trials
bevacizumab
Sensitive
:
C3
bevacizumab
Sensitive: C3 – Early Trials
bevacizumab
Sensitive
:
C3
PD-L1 negative
Non Small Cell Lung Cancer
PD-L1 negative
Non Small Cell Lung Cancer
XTX101
Sensitive: C3 – Early Trials
XTX101
Sensitive
:
C3
XTX101
Sensitive: C3 – Early Trials
XTX101
Sensitive
:
C3
PD-L1 negative
Triple Negative Breast Cancer
PD-L1 negative
Triple Negative Breast Cancer
bevacizumab + atezolizumab
Sensitive: C3 – Early Trials
bevacizumab + atezolizumab
Sensitive
:
C3
bevacizumab + atezolizumab
Sensitive: C3 – Early Trials
bevacizumab + atezolizumab
Sensitive
:
C3
PD-L1 negative
Non Small Cell Lung Cancer
PD-L1 negative
Non Small Cell Lung Cancer
Immunotherapy
Resistant: C3 – Early Trials
Immunotherapy
Resistant
:
C3
Immunotherapy
Resistant: C3 – Early Trials
Immunotherapy
Resistant
:
C3
PD-L1 negative
Squamous Cell Carcinoma of Head and Neck
PD-L1 negative
Squamous Cell Carcinoma of Head and Neck
pembrolizumab + SNS-301
Sensitive: C4 – Case Studies
pembrolizumab + SNS-301
Sensitive
:
C4
pembrolizumab + SNS-301
Sensitive: C4 – Case Studies
pembrolizumab + SNS-301
Sensitive
:
C4
PD-L1 negative
Merkel Cell Carcinoma
PD-L1 negative
Merkel Cell Carcinoma
avelumab
Sensitive: C4 – Case Studies
avelumab
Sensitive
:
C4
avelumab
Sensitive: C4 – Case Studies
avelumab
Sensitive
:
C4
PD-L1 negative
Small Cell Lung Cancer
PD-L1 negative
Small Cell Lung Cancer
pembrolizumab
Sensitive: C4 – Case Studies
pembrolizumab
Sensitive
:
C4
pembrolizumab
Sensitive: C4 – Case Studies
pembrolizumab
Sensitive
:
C4
PD-L1 negative
Small Cell Lung Cancer
PD-L1 negative
Small Cell Lung Cancer
anlotinib + camrelizumab
Sensitive: C4 – Case Studies
anlotinib + camrelizumab
Sensitive
:
C4
anlotinib + camrelizumab
Sensitive: C4 – Case Studies
anlotinib + camrelizumab
Sensitive
:
C4
PD-L1 negative
Colon Cancer
PD-L1 negative
Colon Cancer
SAR445710
Sensitive: D – Preclinical
SAR445710
Sensitive
:
D
SAR445710
Sensitive: D – Preclinical
SAR445710
Sensitive
:
D
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login